Skip to main content

Health condition · Clinically reviewed

Bile duct tumours, from benign lesions to cholangiocarcinoma.

A companion to our cholangiocarcinoma guide - covering the whole spectrum of bile duct growths, how they present and how the UK works them up.

Jump to treatment
A radiographer guides a patient onto the bed of an advanced 3 Tesla MRI scanner in a London imaging suite

Why trust this guide

  • 01

    Clinically reviewed

    Written by our editorial team and reviewed by a registered UK clinician before publication.

  • 02

    Sourced from guidance

    Checked against BSG, NICE, ESMO and peer-reviewed hepatobiliary sources you can see at the end.

  • 03

    Current for 2026

    Reflects modern UK practice including MRCP imaging, SpyGlass cholangioscopy and molecular profiling for cholangiocarcinoma.

Key facts

Bile duct tumours at a glance.

The essentials, in plain English - the spectrum from benign to malignant, how the UK investigates, and why an HPB centre matters.

  • What they are

    A spectrum of growths in the bile ducts, from benign adenomas and inflammatory pseudotumours through premalignant lesions to cholangiocarcinoma.

  • Benign types

    Biliary adenoma, biliary papillomatosis, intraductal papillary neoplasm of bile duct (IPNB), mucinous cystic neoplasm, haemangioma and granular cell tumour.

  • Premalignant

    Biliary intraepithelial neoplasia (BilIN grades 1 to 3) and IPNB with high-grade dysplasia can progress to invasive cancer.

  • Malignant

    Cholangiocarcinoma (intrahepatic, perihilar Klatskin, distal), ampullary carcinoma, gallbladder cancer and metastatic disease.

  • Imaging first

    Ultrasound, MRI with MRCP and contrast CT are the diagnostic backbone, with EUS and ERCP adding tissue where needed.

  • Specialist care

    All bile duct tumours should be reviewed by a hepato-pancreato-biliary (HPB) MDT at a specialist centre.

Why this guide matters

A spectrum, not a single disease.

Bile duct tumours span benign, premalignant and malignant disease - the workup is similar, but the decisions afterwards are very different.

  • Imaging comes first

    MRI with MRCP is the imaging gold standard, mapping the whole biliary tree without invasive tests.

  • Tissue changes the plan

    ERCP with brushings, biopsy and SpyGlass cholangioscopy - and EUS with FNA - turn a suspicious stricture into a definite diagnosis.

  • HPB centres make the difference

    Rare tumours need a specialist HPB MDT: hepatology, oncology, radiology, surgery and clinical nurse specialists working together.

How the diagnosis is made

From first blood test to a clear plan.

The order a UK hepatologist, gastroenterologist or HPB surgeon will normally follow - so you know what to expect and why.

  1. 01

    Assessing

    Bloods and tumour markers

    LFTs (obstructive pattern with raised ALP, GGT and bilirubin), FBC, clotting, plus CA 19-9, CEA and AFP.

  2. 02

    Assessing

    Ultrasound of the liver

    The first imaging test to look for duct dilatation, mass lesions, gallstones and the level of any obstruction.

  3. 03

    Assessing

    MRI liver with MRCP

    The imaging gold standard for the biliary tree, mapping strictures, mass lesions, cysts and vascular anatomy in one non-invasive study.

  4. 04

    Confirming

    Contrast CT chest, abdomen, pelvis

    For staging, vascular involvement and distant disease when a tumour is suspected.

  5. 05

    Confirming

    EUS with FNA

    Endoscopic ultrasound with fine-needle aspiration reaches distal bile duct and ampullary lesions and samples nearby lymph nodes.

  6. 06

    Confirming

    ERCP with brushings and biopsy

    Direct access to the bile duct for brush cytology, forceps biopsy, intraductal ultrasound and SpyGlass cholangioscopy to visualise and biopsy small lesions.

  7. 07

    Preparing

    PET-CT and molecular profiling

    Selective PET-CT for occult metastases, and molecular profiling (FGFR2, IDH1, HER2, BRAF, MSI) if malignancy is confirmed.

Typical timeline: first bloods to MDT decision in one to three weeks at a specialist centre.

Symptoms

What a bile duct tumour can look like.

Presentation depends on location, type and size - many are incidental on scans, others announce themselves with painless jaundice or cholangitis.

  • Painless jaundice

    Yellow skin and eyes, dark urine and pale stools, often the first sign of an obstructing bile duct tumour.

  • Itch (pruritus)

    A relentless whole-body itch from bile salts in the skin, sometimes preceding visible jaundice.

  • Right upper quadrant pain

    A dull ache under the right ribs, sometimes with a heavy or dragging sensation from ductal distension.

  • Cholangitis

    Fever, rigors, jaundice and RUQ pain (Charcot triad) from infection above a partial obstruction.

  • Weight loss and appetite loss

    Unintentional weight loss, early satiety and fatigue point to a systemic or malignant process.

  • Incidental finding

    Many benign tumours and early cholangiocarcinomas are found on scans done for something else.

  • Palpable mass

    A late feature, occasionally including a palpable, non-tender gallbladder (Courvoisier sign) with distal obstruction.

  • Red flag - progressive jaundice

    Painless, progressive obstructive jaundice in an older adult must be investigated urgently for a bile duct or pancreatic tumour.

Treatment

How bile duct tumours are treated in the UK.

From watchful surveillance for tiny benign lesions to Whipple, extended hepatectomy, transplant assessment, systemic therapy and stents.

  • Surveillance for small benign lesions

    Small, asymptomatic biliary adenomas or incidental lesions with clearly benign features may be watched with serial MRCP.

  • Surgical resection - benign

    Symptomatic or growing benign tumours are resected: segmental duct excision, hepatectomy or Whipple depending on location.

  • Extended resection for IPNB

    Intraductal papillary neoplasm of bile duct and biliary papillomatosis have high recurrence and malignant potential and often need extended hepatectomy.

  • Liver transplantation - selective

    Considered for diffuse biliary papillomatosis or early perihilar cholangiocarcinoma within strict criteria at a transplant centre.

  • Curative surgery for cancer

    Resection of intrahepatic, perihilar or distal cholangiocarcinoma when technically feasible and disease is localised.

  • Systemic chemotherapy

    Adjuvant capecitabine after resection, or palliative gemcitabine and cisplatin, often with durvalumab, for advanced cholangiocarcinoma.

  • Targeted and locoregional therapies

    FGFR2, IDH1 and HER2 targeted agents in selected patients, with TACE or TARE (Y90) for liver-confined intrahepatic disease.

  • Biliary drainage

    Endoscopic (ERCP with plastic or metal stents) or percutaneous (PTC) drainage to relieve jaundice before surgery or for palliation.

What this guide is based on

The sources behind every claim on this page.

UK national guidance, international hepatobiliary consensus and specialist charity information, current at the time of last review.

Key references

Guidelines and standards we relied on.

A quiet reminder

This guide is for information, not medical advice.

Your hepatologist, HPB surgeon or oncologist knows your scans and history and can tell you which parts apply to you. If in doubt, get seen.

  • British Society of Gastroenterology. Guidelines on the diagnosis and management of biliary tract cancers.

  • NICE. Suspected cancer: recognition and referral (NG12).

  • ESMO. Clinical practice guideline for biliary tract cancer.

  • AMMF - The Cholangiocarcinoma Charity. Patient information on bile duct cancer and biliary tumours.

Red flags

When a bile duct problem needs urgent attention.

Some scenarios cannot wait for the next outpatient slot - these are the situations that need same-day or urgent specialist review.

  • Progressive painless jaundice

    Painless obstructive jaundice with weight loss in an adult over 40 warrants urgent hepatobiliary imaging and specialist referral.

  • Ascending cholangitis

    Fever, rigors and jaundice with a bile duct obstruction is a life-threatening infection needing IV antibiotics and urgent drainage.

  • Rapidly rising CA 19-9

    A large or rising CA 19-9 with a biliary stricture raises concern for cholangiocarcinoma and needs specialist review.

  • Indeterminate biliary stricture

    A stricture without a clear benign cause needs cholangioscopy, biopsy and MDT discussion before assuming it is benign.

  • Known primary sclerosing cholangitis

    PSC carries a significant lifetime risk of cholangiocarcinoma and any new dominant stricture demands specialist evaluation.

  • Biliary papillomatosis

    Multifocal papillary tumours have a high rate of recurrence and malignant transformation and should be managed in an HPB centre.

  • IPNB with high-grade dysplasia

    A precursor to invasive cholangiocarcinoma - surgical resection at a specialist centre is usually recommended.

  • New mass with liver-fluke exposure

    A history of liver-fluke infection, hepatolithiasis or choledochal cyst raises the pre-test probability of cholangiocarcinoma.

  • Post-ERCP deterioration

    New pain, fever or rising inflammatory markers after ERCP needs urgent reassessment for pancreatitis, cholangitis or perforation.

Living with it

A rare diagnosis, with a specialist pathway.

Four practical things that make the biggest difference - the right team, the right support, timely symptom control and disciplined follow-up.

A quiet reminder

You do not have to be the coordinator.

A specialist HPB nurse can hold the plan across hepatology, oncology, radiology and surgery - ask to be introduced early.

  1. 01 Team

    Insist on an HPB centre

    Bile duct tumours are uncommon and outcomes are better where a specialist HPB MDT sees them regularly.

  2. 02 Support

    Use AMMF

    The UK cholangiocarcinoma charity offers information, peer support and help navigating trials and molecular testing.

  3. 03 Symptoms

    Treat itch and jaundice early

    Biliary drainage transforms symptoms - ask about stenting if jaundice or itch is dominant, even before definitive treatment.

  4. 04 Follow-up

    Stick with surveillance

    Benign and premalignant lesions need serial imaging - do not skip scans, even when you feel well.

Frequently asked

Everything we get asked about bile duct tumours.

Quick answers on benign vs malignant, imaging, ERCP, surgery and what modern cholangiocarcinoma care looks like.

  • What are bile duct tumours?

    A group of growths in the bile ducts that carry bile from the liver and gallbladder to the small intestine. They range from benign adenomas and inflammatory pseudotumours, through premalignant lesions like biliary intraepithelial neoplasia and intraductal papillary neoplasm of the bile duct, to cholangiocarcinoma, ampullary cancer and gallbladder cancer.

  • Are all bile duct tumours cancer?

    No. Many are benign, including biliary adenomas, haemangiomas, granular cell tumours, fibromas and inflammatory pseudotumours. However, some (biliary papillomatosis, IPNB, mucinous cystic neoplasms, BilIN-3) carry a real risk of turning into cancer, which is why every bile duct lesion should be reviewed by a hepato-pancreato-biliary team.

  • What is the difference between this page and your bile duct cancer page?

    This page covers the whole spectrum of bile duct tumours, benign and malignant. Our dedicated /conditions/bile-duct-cancer/ page focuses specifically on cholangiocarcinoma - its staging, surgery, chemotherapy and targeted treatments.

  • How are bile duct tumours investigated?

    With blood tests including LFTs and tumour markers (CA 19-9, CEA, AFP), ultrasound as the first scan, MRI with MRCP as the imaging gold standard, contrast CT for staging, and endoscopic tests (EUS with FNA, ERCP with brushings, biopsy and SpyGlass cholangioscopy) to obtain tissue.

  • How are the benign tumours treated?

    Small, incidental, clearly benign lesions may just be monitored with serial MRCP. Symptomatic or growing lesions are surgically resected - by segmental duct excision, partial hepatectomy or a Whipple procedure depending on location. Biliary papillomatosis and IPNB often need extended resection because of their recurrence and cancer risk.

  • What if my tumour is a cholangiocarcinoma?

    Treatment follows our /conditions/bile-duct-cancer/ pathway: curative surgery where possible with adjuvant capecitabine, palliative gemcitabine and cisplatin (often with durvalumab), targeted therapies for FGFR2, IDH1 or HER2 alterations, locoregional treatments such as TACE or TARE Y90 for liver-confined disease, and biliary drainage stents to control jaundice.

Related content

Keep reading.

Pulse Healthcare concierge

Send us your enquiry

A concierge service for UK private healthcare. We match you with the best vetted clinics and consultants in our network - they then contact you directly.

So we can match you to the right clinician close to you.

We reply to every enquiry within 24 hours (Mon–Fri). Confidential - your details are never shared outside our vetted consultant network.